Eliza began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care. Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.
Latest from Eliza Slawther
The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.
Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.
A European Medicines Agency official provided an overview and update of the support the EMA offers developers of innovative products and discussed, among other things, its Innovation Task Force, Quality Innovation Group and a scientific advice pilot for clinical trials.
The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.
The European Medicines Agency says that a regulatory reliance pilot that it is supporting to speed up assessments of post-approval changes appears to be accelerating evaluation timelines in non-EU countries.
Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.